Skip to main content
Erschienen in: Endocrine Pathology 4/2015

01.12.2015

Analysis of Amyloid in Medullary Thyroid Carcinoma by Mass Spectrometry-Based Proteomic Analysis

verfasst von: Lori A. Erickson, Julie A. Vrana, Jason Theis, Michael Rivera, Ricardo V. Lloyd, Ellen McPhail, Jun Zhang

Erschienen in: Endocrine Pathology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Amyloid is a characteristic histologic feature in medullary thyroid carcinomas (MTC). We utilized a novel mass spectrometry-based proteomic analysis to determine if we could identify specific proteins associated with amyloid in MTC. We studied 9 MTC (1 multiple endocrine neoplasia type 2A, 1 familial MTC, and 7 sporadic). Laser microdissection was utilized to sample the amyloid which was then trypsin digested and evaluated by liquid chromatography electrospray tandem MS (LC-MS/MS) which identified the presence of amyloidogenic proteins in all cases of MTC. High levels of calcitonin were identified in all 9 cases of MTC. Secretogranin-1 was identified in 6 of 9 MTC. Calcitonin gene-related peptide was identified in 4 of 9 cases of MTC. LC-MS/MS proteomic analysis provides a rapid, highly specific, and sensitive method for identification of the specific type of amyloid in these endocrine tumors. This approach may allow classification of different forms of endocrine amyloid present in neuroendocrine tumors.
Literatur
1.
Zurück zum Zitat Vrana JA, Gamez JD, Madden BJ et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 114(24):4957–4959, 2009.CrossRefPubMed Vrana JA, Gamez JD, Madden BJ et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 114(24):4957–4959, 2009.CrossRefPubMed
2.
Zurück zum Zitat Dasari S, Theis JD, Vrana JA et al. Clinical proteome informatics workbench detects pathogenic mutations in hereditary amyloidoses. J Proteome Res. 13(5):2352–23588, 2014CrossRefPubMed Dasari S, Theis JD, Vrana JA et al. Clinical proteome informatics workbench detects pathogenic mutations in hereditary amyloidoses. J Proteome Res. 13(5):2352–23588, 2014CrossRefPubMed
3.
Zurück zum Zitat Vrana JA, Theis JD, Dasari S, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica. 99(7):1239–1247, 2014.PubMedCentralCrossRefPubMed Vrana JA, Theis JD, Dasari S, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica. 99(7):1239–1247, 2014.PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Sethi S, Vrana JA, Theis JD, Dogan A. Mass spectrometry based proteomics in the diagnosis of kidney disease. Curr Opin Nephrol Hypertens. 22(3):273–80, 2013.CrossRefPubMed Sethi S, Vrana JA, Theis JD, Dogan A. Mass spectrometry based proteomics in the diagnosis of kidney disease. Curr Opin Nephrol Hypertens. 22(3):273–80, 2013.CrossRefPubMed
5.
Zurück zum Zitat Maleszewski JJ, Murray DL, Dispenzieri A, et al. Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovasc Pathol. 22(3):189–194, 2013.CrossRefPubMed Maleszewski JJ, Murray DL, Dispenzieri A, et al. Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovasc Pathol. 22(3):189–194, 2013.CrossRefPubMed
6.
Zurück zum Zitat Albores-Saavedra J, Rose GG, Ibanez ML et al. The amyloid in solid carcinoma of the thyroid gland: staining characteristics, tissue cultures and electron microscopic observations. Lab Invest 13:77–89, 1964.PubMed Albores-Saavedra J, Rose GG, Ibanez ML et al. The amyloid in solid carcinoma of the thyroid gland: staining characteristics, tissue cultures and electron microscopic observations. Lab Invest 13:77–89, 1964.PubMed
7.
Zurück zum Zitat Meyer JS. Fine structure of two amyloid-forming medullary carcinomas of thyroid. Cancer 21(3):406–425, 1968.CrossRefPubMed Meyer JS. Fine structure of two amyloid-forming medullary carcinomas of thyroid. Cancer 21(3):406–425, 1968.CrossRefPubMed
8.
Zurück zum Zitat Meyer JS, Hutton WE, Kenny AD. Medullary carcinoma of thyroid gland. Subcellular distribution of calcitonin and relationship between granules and amyloid. Cancer 31(2):433–41, 1973CrossRefPubMed Meyer JS, Hutton WE, Kenny AD. Medullary carcinoma of thyroid gland. Subcellular distribution of calcitonin and relationship between granules and amyloid. Cancer 31(2):433–41, 1973CrossRefPubMed
9.
Zurück zum Zitat Arnal-Monreal FM, Goltzman D, Knaack J, Wang NS, Huang SN. Immunohistologic study of thyroidal medullary carcinoma and pancreatic insulinoma. Cancer 40(3):1060–1070, 1977.CrossRefPubMed Arnal-Monreal FM, Goltzman D, Knaack J, Wang NS, Huang SN. Immunohistologic study of thyroidal medullary carcinoma and pancreatic insulinoma. Cancer 40(3):1060–1070, 1977.CrossRefPubMed
10.
Zurück zum Zitat Sletten K, Westermark P, Natvig JB. Characterization of amyloid fibril proteins from medullary carcinoma of the thyroid. J Exp Med 143(4):993–998, 1976.CrossRefPubMed Sletten K, Westermark P, Natvig JB. Characterization of amyloid fibril proteins from medullary carcinoma of the thyroid. J Exp Med 143(4):993–998, 1976.CrossRefPubMed
11.
Zurück zum Zitat Khurana R, Agarwal A, Bajpai VK, et al. Unraveling the amyloid associated with human medullary thyroid carcinoma. Endocrinology 145(12):5465–5470, 2004.CrossRefPubMed Khurana R, Agarwal A, Bajpai VK, et al. Unraveling the amyloid associated with human medullary thyroid carcinoma. Endocrinology 145(12):5465–5470, 2004.CrossRefPubMed
12.
Zurück zum Zitat Sipe JD, Benson MD, Buxbaum JN, Ikeda, S, Merlini G, Saraiva MJM, Westermark P. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 21(4):221–224, 2014.CrossRefPubMed Sipe JD, Benson MD, Buxbaum JN, Ikeda, S, Merlini G, Saraiva MJM, Westermark P. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 21(4):221–224, 2014.CrossRefPubMed
13.
Zurück zum Zitat Knowles TPJ, Vendruscolo M, Dobson CM. The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol 15:384–396, 2014.CrossRefPubMed Knowles TPJ, Vendruscolo M, Dobson CM. The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol 15:384–396, 2014.CrossRefPubMed
14.
Zurück zum Zitat Chiti F and Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Bioch 75:333–366, 2006.CrossRef Chiti F and Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Bioch 75:333–366, 2006.CrossRef
15.
Zurück zum Zitat Benedum UM, Lamouroux A, Konecki DS, et al. The Primary structure of human secretogranin I (chromogranin B): comparison with chromogranin A reveals homologous terminal domains and a large intervening variable region. EMBO J 6(5): 1203–1211, 1987.PubMedCentralPubMed Benedum UM, Lamouroux A, Konecki DS, et al. The Primary structure of human secretogranin I (chromogranin B): comparison with chromogranin A reveals homologous terminal domains and a large intervening variable region. EMBO J 6(5): 1203–1211, 1987.PubMedCentralPubMed
16.
Zurück zum Zitat Durham P and Russo A. Stimulation of the calcitonin gene-related peptide enhancer by mitogen-activated protein kinases and repression by an antimigraine drug in trigeminal ganglia neurons. J Neurosci 23(3):807–815, 2003PubMed Durham P and Russo A. Stimulation of the calcitonin gene-related peptide enhancer by mitogen-activated protein kinases and repression by an antimigraine drug in trigeminal ganglia neurons. J Neurosci 23(3):807–815, 2003PubMed
17.
Zurück zum Zitat Schafers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 23(7):2517–2521, 2003.PubMed Schafers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 23(7):2517–2521, 2003.PubMed
18.
Zurück zum Zitat Arulmani U, VanDenBrink AM, Villalon CM, Saxena PR. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 500(1–3):315–330, 2004.CrossRefPubMed Arulmani U, VanDenBrink AM, Villalon CM, Saxena PR. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 500(1–3):315–330, 2004.CrossRefPubMed
19.
Zurück zum Zitat Russell FA, King R, Smillie SJ, et al. Calcitonin gene-related peptide: physiology and pathophysiology. Brain Physiological Reviews 94(4):1099–1142, 2014.CrossRefPubMed Russell FA, King R, Smillie SJ, et al. Calcitonin gene-related peptide: physiology and pathophysiology. Brain Physiological Reviews 94(4):1099–1142, 2014.CrossRefPubMed
Metadaten
Titel
Analysis of Amyloid in Medullary Thyroid Carcinoma by Mass Spectrometry-Based Proteomic Analysis
verfasst von
Lori A. Erickson
Julie A. Vrana
Jason Theis
Michael Rivera
Ricardo V. Lloyd
Ellen McPhail
Jun Zhang
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 4/2015
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-015-9390-7

Weitere Artikel der Ausgabe 4/2015

Endocrine Pathology 4/2015 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …